Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000732366 | SCV000532435 | uncertain significance | not provided | 2023-04-03 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge; In silico analysis is inconclusive as to whether the variant alters gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown. |
Eurofins Ntd Llc |
RCV000732366 | SCV000860318 | uncertain significance | not provided | 2018-03-29 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001087449 | SCV001008000 | likely benign | Hereditary spastic paraplegia 11 | 2023-12-28 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001848788 | SCV002105680 | uncertain significance | Hereditary spastic paraplegia | 2017-03-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002446735 | SCV002736252 | likely benign | Inborn genetic diseases | 2019-07-11 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |